Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Short Interest Update

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) saw a significant decrease in short interest in the month of February. As of February 28th, there was short interest totalling 3,940,000 shares, a decrease of 14.9% from the February 13th total of 4,630,000 shares. Based on an average daily volume of 895,400 shares, the short-interest ratio is currently 4.4 days. Approximately 7.1% of the company’s stock are sold short.

Insider Buying and Selling

In other Agios Pharmaceuticals news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the completion of the transaction, the insider now owns 18,906 shares of the company’s stock, valued at approximately $608,395.08. This trade represents a 12.92 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.93% of the stock is owned by insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in shares of Agios Pharmaceuticals by 1.5% in the 4th quarter. Vanguard Group Inc. now owns 5,631,321 shares of the biopharmaceutical company’s stock worth $185,045,000 after buying an additional 85,339 shares during the last quarter. State Street Corp increased its position in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after acquiring an additional 216,484 shares during the last quarter. Erste Asset Management GmbH bought a new position in Agios Pharmaceuticals in the third quarter valued at about $97,199,000. Jefferies Financial Group Inc. purchased a new position in Agios Pharmaceuticals in the fourth quarter worth about $49,290,000. Finally, Geode Capital Management LLC boosted its position in Agios Pharmaceuticals by 0.5% in the third quarter. Geode Capital Management LLC now owns 1,357,531 shares of the biopharmaceutical company’s stock worth $60,326,000 after purchasing an additional 6,101 shares during the last quarter.

Wall Street Analyst Weigh In

Several research firms recently weighed in on AGIO. Cantor Fitzgerald restated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. HC Wainwright assumed coverage on Agios Pharmaceuticals in a research note on Monday, February 24th. They issued a “buy” rating and a $58.00 target price on the stock. StockNews.com lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, February 14th. Royal Bank of Canada increased their price objective on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Finally, Scotiabank raised their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $56.57.

Agios Pharmaceuticals Stock Performance

NASDAQ AGIO opened at $31.68 on Thursday. Agios Pharmaceuticals has a one year low of $27.14 and a one year high of $62.58. The stock has a 50-day moving average of $33.51 and a 200 day moving average of $41.49. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of 2.79 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts’ consensus estimates of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. On average, equities analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.